Correction: Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor

Suyoun Chung; Kyoko Kijima; Aiko Kudo; Yoshiko Fujisawa; Yosuke Harada; Akiko Taira; Naofumi Takamatsu; Takashi Miyamoto; Yo Matsuo; Yusuke Nakamura

doi:10.18632/oncotarget.27755

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor

PDF | How to cite

Oncotarget. 2020; 11:3749-3750. https://doi.org/10.18632/oncotarget.27755

Metrics: PDF 933 views | ?

Suyoun Chung¹, Kyoko Kijima¹, Aiko Kudo¹, Yoshiko Fujisawa¹, Yosuke Harada¹, Akiko Taira¹, Naofumi Takamatsu¹, Takashi Miyamoto¹, Yo Matsuo¹ and Yusuke Nakamura²

¹ OncoTherapy Science, Inc., Kawasaki, Kanagawa, Japan
² Department of Medicine and Surgery, The University of Chicago, Chicago, IL, USA

Published: October 13, 2020

Copyright: © 2020 Chung et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: During image assembly, incorrect data was mistakenly used in Figure 5A, resulting in a duplicate image of the bottom two panels. The corrected Figure 5A is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2016; 7:18171–18182. DOI: https://doi.org/10.18632/oncotarget.7685.

Figure 5: Molecular changes in OTS167-treated tumor tissue. Immunohistochemical analysis using xenograft tissue collected on day 4. (A) DEPDC1, (B) FOXM1, (C) p21, and (D) p53 were examined (original magnification: x 400). Box plots represent the percentage of positive cells stained with each antibody. Horizontal lines represent mean and error bars indicating the interquartile ranges of 30 ROIs per group. *p < 0.0001 by ANOVA and t t-test.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27755

Publication Alerts

Corrections:

Correction: Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor